The high‐resolution X‐ray structures of the model protein lysozyme in the presence of the potential drug [V IV O(acetylacetonato) 2 ] from crystals grown in 1.1 M NaCl, 0.1 M sodium acetate at pH 4.0 reveal the binding to the protein of different and unexpected mixed‐valence cage‐like polyoxidovanadates (POVs): [V 15 O 36 (OH 2 )] 5− , which non‐covalently interacts with the lysozyme surface, [V 15 O 33 (OH 2 )] + and [V 20 O 51 (OH 2 )] n− (this latter based on an unusual {V 18 O 43 } cage) which covalently bind the protein. EPR spectroscopy confirms the partial oxidation of V IV to V V and the formation of mixed‐valence species. The results indicate that the interaction with proteins can stabilize the structure of unexpected – both for dimension and architecture – POVs, not observed in aqueous solution.
No takes yet. Share an insight, caveat, or question.
Tito et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: